HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Talks Drug Safety With China, But Visas Still Elusive For Staff

This article was originally published in The Tan Sheet

Executive Summary

The agency is unable to place more inspectors in China even as Howard Sklamberg, deputy commissioner for global regulatory operations and policy, visits Beijing.

You may also be interested in...



How FDA Plans To Stop Worrying And Love Globalization

New deputy commissioner Howard Sklamberg tells “The Pink Sheet” that globalization of the drug supply eventually will become more commonplace, and ideally less of a concern, for American consumers.

FDA Inspection Growth In China Stymied By Visa Issues

The agency is waiting for approval to locate 10 new drug inspectors in China.

FDA Counterfeit Screening Tool Gets Field Test In Ghana; Corning Prepares Device For Mass Production

FDA currently employs the CD3 in its laboratories and at a number of international mail facilities and other points of entry to the U.S. to screen cosmetics, foods, medical devices and cigarettes, as well as drugs.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS139666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel